We are joined by our Editor-in-Chief for European Oncology & Haematology, Axel S Merseburger, to discuss the recent results of the OLYMPUS trial, an ongoing, single-arm, multicenter trial enrolling 71 patients with treatment-naïve or recurrent low-grade non-invasive UTUC with at least one measurable papillary tumor located above the ureteropelvic junction.
For further information on this trial, please follow the following links
1. Before the approval of mitomycin pyelocalyceal, how was low-grade upper tract urothelial cancer treated, and what are the treatment challenges associated with the upper urinary tract? (0:06)
2. How is the gel administered and what is the treatment regimen? (0:52)
3. Could you tell us about the aims, design and inclusion criteria of the OLYMPUS trial? (1:56)
4. What were the major efficacy and safety findings of this trial? (3:16)
5. What patients are most likely to benefit from this therapy and how might it impact the future of urothelial cancer? (4:10)
Axel S Merseburger has no conflicts of interest to declare in relation to this video.
Commissioned, edited and funded by Touch Medical Media
Published: 14 May 2020
Share this Video
Related Videos In Genitourinary Cancers
Stephen B Williams, ASCO 2021: TAR-200 in Combination with Cetrelimab in Muscle-invasive Urothelial Carcinoma of the Bladder
touchONCOLOGY joins Professor Stephen B Williams (Chief, Division of Urology, Professor of Urology and Radiology, Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA) at ASCO 2021 to discuss the efficacy of TAR-200 in combination with cetrelimab in participants with muscle-invasive urothelial carcinoma of the bladder. The abstract ‘A phase 3, multicenter, […]
Joaquim Bellmunt, ASCO 2021: 5-year Follow-up from the Phase 3 KEYNOTE-045 Trial
touchONCOLOGY joins Dr Joaquim Bellmunt (Director, Bladder Cancer Program, Beth Israel Deaconess Medical Center; Associate Professor of Medicine, Harvard Medical School, Boston, MA, USA) at ASCO 2021 to discuss the 5-year follow-up from the phase 3 KEYNOTE-045 trial. The abstract ‘A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial […]
Axel Merseburger, ASCO GU 2021: Apalutamide in Metastatic Castration-sensitive Prostate Cancer
We were delighted to talk to Editor-in-Chief Prof. Axel Merseburger (Professor and Chairman, Department of Urology, University of Lübeck, Lübeck, Germany) around the TITAN trial in metastatic castration-sensitive prostate cancer (ClinicalTrials.gov Identifer: NCT02489318). The abstract “Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!